BACKGROUND: Emergence of HIV-1 drug resistance is at times an inevitable and anticipated consequence of antiretroviral therapy (ART) failure. We examined drug resistance patterns and virus re-suppression among subtype C-infected South African patients receiving first-line ART. METHODS: Treatment records of 431 patients on NNRTI-containing regimens for a median of 45 months were analyzed. Patients with viral load (VL) >400 copies/mL were followed and drug resistance mutations (DRM) were re-assessed. Associations between clinical/demographic measures and drug resistance/virologic outcomes were examined using Fisher exact and ordinal and logistic regression. RESULTS: Ten percent of patients (43/431) were viremic at enrollment (98% previously suppressed); sequences were obtained from 38/43. Of those, 82% had 1-7 DRM. In bivariate analysis remote exposure to single-dose nevirapine or prior ART; higher CD4 counts; lower VL; and >6 months of virologic failure were significantly associated with number of DRM. Of 25 viremic patients followed for a median of 8 months on a continued first-line regimen, 12 (48%) re-suppressed, six with K103N and three with M184V. Thirteen (52%) had continued virologic failure which was significantly associated with detectable VL>6 months prior to enrollment and number of DRM. CONCLUSION: Among these HIV-1 subtype C-infected patients, DRM numbers and patterns were associated with prior exposure to sub-optimal ART, adherence and duration of virologic failure. Viral re-suppression in the presence of K103N and M184V challenges assumptions about drug resistance. In resource-limited settings, where genotyping and alternative drug options are unavailable, continuing first-line treatment, reinforcing adherence and regular virologic monitoring may be effective even after virologic failure.
BACKGROUND: Emergence of HIV-1 drug resistance is at times an inevitable and anticipated consequence of antiretroviral therapy (ART) failure. We examined drug resistance patterns and virus re-suppression among subtype C-infected South African patients receiving first-line ART. METHODS: Treatment records of 431 patients on NNRTI-containing regimens for a median of 45 months were analyzed. Patients with viral load (VL) >400 copies/mL were followed and drug resistance mutations (DRM) were re-assessed. Associations between clinical/demographic measures and drug resistance/virologic outcomes were examined using Fisher exact and ordinal and logistic regression. RESULTS: Ten percent of patients (43/431) were viremic at enrollment (98% previously suppressed); sequences were obtained from 38/43. Of those, 82% had 1-7 DRM. In bivariate analysis remote exposure to single-dose nevirapine or prior ART; higher CD4 counts; lower VL; and >6 months of virologic failure were significantly associated with number of DRM. Of 25 viremic patients followed for a median of 8 months on a continued first-line regimen, 12 (48%) re-suppressed, six with K103N and three with M184V. Thirteen (52%) had continued virologic failure which was significantly associated with detectable VL>6 months prior to enrollment and number of DRM. CONCLUSION: Among these HIV-1 subtype C-infectedpatients, DRM numbers and patterns were associated with prior exposure to sub-optimal ART, adherence and duration of virologic failure. Viral re-suppression in the presence of K103N and M184V challenges assumptions about drug resistance. In resource-limited settings, where genotyping and alternative drug options are unavailable, continuing first-line treatment, reinforcing adherence and regular virologic monitoring may be effective even after virologic failure.
Authors: Vlad Novitsky; C William Wester; Victor DeGruttola; Hermann Bussmann; Simani Gaseitsiwe; Ann Thomas; Sikhulile Moyo; Rosemary Musonda; Erik Van Widenfelt; Richard G Marlink; M Essex Journal: AIDS Res Hum Retroviruses Date: 2007-07 Impact factor: 2.205
Authors: Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme Journal: Bioinformatics Date: 2005-08-02 Impact factor: 6.937
Authors: Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood Journal: Antivir Ther Date: 2007
Authors: Neil Martinson; Lerato Mohapi; Darryl Bakos; Glenda E Gray; James A McIntyre; Charles B Holmes Journal: J Acquir Immune Defic Syndr Date: 2009-03-01 Impact factor: 3.731
Authors: Richard A Murphy; Henry Sunpath; Carmen Castilla; Shameez Ebrahim; Richard Court; Hoang Nguyen; Daniel Kuritzkes; Vincent C Marconi; Jean B Nachega Journal: J Acquir Immune Defic Syndr Date: 2012-10-01 Impact factor: 3.731
Authors: Mark J Siedner; Mwebesa B Bwana; Mahomed-Yunus S Moosa; Michelle Paul; Selvan Pillay; Suzanne McCluskey; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi Journal: HIV Clin Trials Date: 2017-07-18
Authors: Christopher J Hoffmann; Salome Charalambous; Alison D Grant; Lynn Morris; Gavin J Churchyard; Richard E Chaisson Journal: Trop Med Int Health Date: 2014-02 Impact factor: 2.622
Authors: Mark J Siedner; Mahomed-Yunus S Moosa; Suzanne McCluskey; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Melendhran Pillay; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Rajesh T Gandhi; Brent A Johnson; Henry Sunpath; Mwebesa B Bwana; Vincent C Marconi Journal: Ann Intern Med Date: 2021-10-26 Impact factor: 51.598
Authors: Sarah E Rutstein; Mina C Hosseinipour; Deborah Kamwendo; Alice Soko; Memory Mkandawire; Andrea K Biddle; William C Miller; Morris Weinberger; Stephanie B Wheeler; Abdoulaye Sarr; Sundeep Gupta; Frank Chimbwandira; Reuben Mwenda; Steve Kamiza; Irving Hoffman; Ronald Mataya Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Ujjwal Neogi; Elsa Heylen; Anita Shet; Sara Chandy; Ranjani Shamsunder; Anders Sönnerborg; Maria L Ekstrand Journal: PLoS One Date: 2013-01-30 Impact factor: 3.240